The long-standing relationship between drug developers and academia is changing, with big pharma seeking broader and more direct access to innovative research being done at universities. But as the captains of the drug industry cozy up to the ivory towers, it remains to be seen what role the venture capitalists and biotechs that have historically served as middle-men between these two parties will play.